Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer

This phase II trial assessed the toxicity and efficacy of irinotecan plus docetaxel in cisplatin-pretreated oesophageal cancer. Irinotecan 160 mg m(−2) plus docetaxel 65 mg m(−2) once every 3 weeks led to severe myelosuppression in four patients, all of whom experienced neutropenic fever. After amen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lordick, F, von Schilling, C, Bernhard, H, Hennig, M, Bredenkamp, R, Peschel, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376928/
https://www.ncbi.nlm.nih.gov/pubmed/12915869
http://dx.doi.org/10.1038/sj.bjc.6601168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376928/
https://www.ncbi.nlm.nih.gov/pubmed/12915869
http://dx.doi.org/10.1038/sj.bjc.6601168

Ejemplares similares